Literature DB >> 32909698

Use of complementary therapies for chronic pain management in patients with reported Ehlers-Danlos syndrome or hypermobility spectrum disorders.

Jessica S Demes1, Bryan McNair2, Matthew R G Taylor3.   

Abstract

Ehlers-Danlos Syndromes (EDS) and related Hypermobility Spectrum Disorders (HSD) are debilitating connective tissue disorders that feature a prominent pain component for which there are limited therapeutic options for pain management. Consequently, many patients try various non-prescribed treatments, including complementary and alternative therapies that have not been well studied in the EDS/HSD patient population. We surveyed over 500 individuals through the EDS Society who reported having been diagnosed with EDS or HSD to ascertain what complementary and alternative therapies were used and their reported effectiveness in alleviating pain and improving quality of life. Specifically, we focused on the use of traditional Chinese therapies, herbal medications, and marijuana. The most commonly reported therapies, used by 70-92% of participants, were non-steroidal anti-inflammatory drugs, acetaminophen, opioids, and physical therapy. Therapies rated by participants as most efficacious were opioids, physical therapy, and marijuana with 10-24% of those using these therapies rating them as extremely helpful. Patient-initiated complementary therapy use in EDS/HSD patients is widespread at 56%. Complementary therapies were largely utilized by EDS/HSD patients with higher reported pain levels. Providers caring for EDS/HSD patients should be aware of these data showing broad usage of predominantly non-prescribed therapies and be prepared to consider such usage in working collaboratively with these patients to develop comprehensive treatment plans to manage their chronic pain complications.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Ehlers-Danlos; complementary therapy; hypermobility Spectrum disorders; joint hypermobility; marijuana; pain management

Mesh:

Substances:

Year:  2020        PMID: 32909698     DOI: 10.1002/ajmg.a.61837

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  4 in total

1.  Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?

Authors:  Bérengère Aubry-Rozier; Adrien Schwitzguebel; Flore Valerio; Joelle Tanniger; Célia Paquier; Chantal Berna; Thomas Hügle; Charles Benaim
Journal:  Rheumatol Int       Date:  2021-08-16       Impact factor: 2.631

2.  High rate of dyspareunia and probable vulvodynia in Ehlers-Danlos syndromes and hypermobility spectrum disorders: An online survey.

Authors:  Jennifer E Glayzer; Barbara L McFarlin; Marco Castori; Marie L Suarez; Monya C Meinel; William H Kobak; Alana D Steffen; Judith M Schlaeger
Journal:  Am J Med Genet C Semin Med Genet       Date:  2021-11-07       Impact factor: 3.359

3.  Comparison and correlation of cervical proprioception and muscle endurance in general joint hypermobility participants with and without non-specific neck pain-a cross-sectional study.

Authors:  Ravi Shankar Reddy; Jaya Shanker Tedla; Mastour Saeed Alshahrani; Faisal Asiri; Venkata Nagaraj Kakaraparthi
Journal:  PeerJ       Date:  2022-03-11       Impact factor: 2.984

Review 4.  Multidisciplinary Approach to Treating Chronic Pain in Patients with Ehlers-Danlos Syndrome: Critically Appraised Topic.

Authors:  Kiley C Whalen; Wilson Crone
Journal:  J Pain Res       Date:  2022-09-13       Impact factor: 2.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.